MarketPulse

pulmonary arterial hypertension

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gossamer Bio Stock Crashes 80% on Failed Trial; Class Action Lawsuit Filed Over Alleged Investor Deception

Gossamer Bio ($GOSS) faces class action lawsuit after Phase 3 trial failure caused 80% stock plunge. Investors allege management misled them about trial design despite knowing of critical issues.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gossamer Bio Plummets 80% as Failed Phase 3 Trial Triggers Securities Lawsuit

Gossamer Bio faces class action lawsuit after Phase 3 PROSERA trial failure causes 80% stock collapse. Allegations include investor misleading on trial design and patient recruitment.
GOSSsecurities class actionstock price drop
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Gossamer Bio Stock Collapses 80% on Trial Data Disclosure; Securities Lawsuit Filed

Gossamer Bio faces securities fraud lawsuit after stock plummets 80% following disclosure of allegedly undisclosed Latin American trial site enrollment practices that compromised Phase 3 study results. Lead plaintiff deadline is June 1, 2026.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Gainey Mckenna & Egleston

Gossamer Bio Faces Class Action Over Failed PAH Study, Stock Plummets 80%

Gossamer Bio ($GOSS) faces class action lawsuit over failed PROSERA PAH trial; stock crashed 80% to $0.42 per share on February 23, 2026, amid allegations of misleading investor statements.
GOSSsecurities fraudclass action lawsuit
BenzingaBenzinga··Vandana Singh

United Therapeutics Surges 16.5% on Positive Lung Disease Trial Results

United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.
UTHRFDA approvalclinical trial
The Motley FoolThe Motley Fool··Cory Renauer

Liquidia CCO Liquidates $2.8M Stock Position Amid Strong Product Sales Growth

Liquidia's Chief Commercial Officer sold 80,000 shares worth $2.8M through pre-arranged plan while retaining substantial holdings as flagship product Yutrepia drives record quarterly profits.
LQDAbiotechnologyinsider sale
BenzingaBenzinga··Vandana Singh

United Therapeutics' Ralinepag Shows 55% Drop in PAH Worsening, Stock Soars

United Therapeutics ($UTHR) stock rallies 3.98% after Phase 3 trial shows ralinepag reduces PAH worsening 55%, with FDA filing targeted for mid-2026.
UTHRFDA approvalPhase 3 trial